ArticleEuropean radiology2025
White matter structure-function coupling alteration is associated with plasma biomarkers and cognition in Alzheimer's disease.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The nature and interpretation of BOLD signals in white matter - A review.Magnetic resonance imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThere were white matter (WM) microstructural abnormalities in Alzheimer's disease (AD), and it may affect information transmission along WM tracts. We aim to investigate AD-related changes in the structure-function coupling of WM and their associations with AD plasma biomarkers and cognitive performance.
methodsThis retrospective study evaluated participants who provided blood samples, underwent MR brain scans, and completed neuropsychological assessments. Plasma biomarker levels of β-amyloid (Aβ), phosphorylated tau181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured using the Single Molecule Array platform. We used a structure-function coupling approach, combining spatial-temporal correlations of functional signals with diffusion tensor orientations in the WM circuit derived from functional and diffusion magnetic resonance imaging (MRI). Association and mediation analyses were conducted to explore the relationships among plasma biomarkers, structure-function coupling, and cognitive performance in AD.
resultsCompared with the cognitively normal (CN) and mild cognitive impairment (MCI) groups, the AD dementia group showed a widespread increase in structure-function coupling within WM regions, including the body and splenium of the corpus callosum. Additionally, structure-function coupling in WM tracts was significantly associated with the levels of p-tau181 and NfL. Moreover, structure-function coupling mediated the relationship between memory and the level of p-tau181 or NfL.
conclusionOur findings suggest that there is altered information transmission along WM tracts in patients with AD. The brain structure-function coupling is associated with plasma biomarkers and cognitive scores, suggesting that abnormal signal transfer of neuronal fiber pathways could be a potential mechanism of AD neuropathology. KEY POINTS: Question White matter (WM) microstructural abnormalities may affect information transmission along WM tracts, resulting in cognitive decline in Alzheimer's disease (AD). Findings The AD dementia group showed a widespread increase in structure-function coupling within WM regions, which was associated with plasma biomarkers and cognitive scores. Clinical relevance The brain structure-function coupling is associated with plasma biomarkers and cognitive scores, suggesting that abnormal signal transfer of neuronal fiber pathways could be a potential mechanism of the neuropathology of AD.
Indexed as
Identifiers
40413663What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.